PSTX - Poseida Corp Forward Price-to-Revenue Multiple

poseida.com (PSTX) - corporate logo

Poseida Therapeutics (PSTX) generates revenue by creating innovative treatments for oncology and rare blood pathologies through partnerships. The forward price-to-sales ratio on the GURU.Markets chart illustrates the asset valuation trend, where 6.20 becomes the new value of the indicator. Returns are based on piggyBac platform licenses, while development relies on strategic alliances with pharma behemoths that fund clinical trials.

poseida.com - PSTX Projected Price to Revenue (period 07/04/2022 - 01/18/2025)

Poseida Corp - analytical breakdowns and key metrics (PSTX)

- market price and analyst price targets:
Price Chart Poseida Therapeutics, Inc.|PSTX - Price Target Chart
- market capitalization statistics:
Market Valuation Poseida Corp|PSTX - Value Adjusted for Debt and Cash
- business book valuation details:
Book Value per Share Poseida Therapeutics|PSTX - Book Value of Business|Market Capitalization to Book Value Ratio poseida.com|PSTX - Company Assets
- debt and solvency information:
Debt to Equity Poseida Therapeutics|PSTX - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Poseida Therapeutics|PSTX - Company Cumulative Debt|Debt to Book Value Poseida Corp|PSTX - Company Long-Term Loans and Borrowings|Company Current Liabilities Poseida Therapeutics|Quick Ratio poseida.com
- financial results and valuation multiples details:
PSTX - Final Profit|Projected Future Earnings Poseida Therapeutics|PSTX - Market Cap to Earnings|Future Price to Earnings Poseida|PSTX - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Poseida Corp|PSTX - Operating profit EBITDA|Earnings per share for the last twelve months Poseida Therapeutics|PSTX - Earnings per one share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months poseida.com|PSTX - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Poseida Therapeutics
- revenue and sales proceeds data:
PSTX - Company Annual Revenue|Company Projected Revenue Poseida Therapeutics, Inc.|PSTX - Price to Sales|Price-to-Projected Revenue Ratio Poseida Corp
Initial company analysis:Poseida Therapeutics, Inc. (PSTX)
Original product of Poseida Corp

For Poseida Therapeutics (PSTX), the projected market capitalization-to-revenue ratio reflects market expectations for the commercialization of cell therapy, provided there is an absence of drug toxicity and successful production scaling. This multiple correlates the current business value with expected revenues, allowing investors to track the systemic revaluation of the asset based on macroeconomic conditions and the effectiveness of targeted tumor impact.

Key competitors

Price-to-Projected Revenue Ratio Legend Biotech Corporation LEGN|Sana Biotechnology Inc - Price-to-Projected Revenue Ratio|AUTL: Forward Price-to-Revenue Multiple|Forward Price to Sales ALLO (Allogene Corp)|RNAC: Forward P/S Multiple|Projected Price to Revenue Cellectis CLLS|CRBU (Caribou Biosciences, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Instil Bio Inc. TIL|Price-to-Projected Revenue Ratio Genenta Science S.p.A. (GNTA)|centurytx.com - Market Cap to Projected Revenue|Forward P/S Multiple JSPR (Jasper Therapeutics, Inc.)|Senti Bio (SNTI) - Market Cap to Future Revenue Ratio|ADAP: Forward Price-to-Revenue Multiple|Forward Price to Sales CERO (CERo Therapeutics)|TCRT (alaunos.com) - Forward Price-to-Revenue Multiple|ACHL: Price to Expected Revenue Ratio|CRGX (CARGO Therapeutics) - Forward P/S Multiple|TSVT: Forward Price to Sales|Forward P/S Multiple GRCL